Genmab's successful CEO dismisses retirement plans
Wednesday, Genmab CEO Jan van de Winkel presented yet another guidance upgrade. Even though he has passed 60 years of age, he underscores his intention to remain on board with the company for many years yet.
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL FRANK CHRISTENSEN
This Wednesday was in many ways "just another day at the office" for Genmab Chief Executive Jan van de Winkel.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Darzalex sales exceed expectations in second quarter
For subscribers
Genmab surpasses 1,000 employees
For subscribers
